Compare Globus Medical Inc. Class A Common Stock (GMED) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares 3 7 Year Treasury Bond ETF trades at $112.65 (market cap $16.78B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares 3 7 Year Treasury Bond ETF for 45 Days on average.
| GMED | IEI | |
|---|---|---|
Market Cap | $10.25B | $16.78B |
Volume | 1,108,124 | 2,469,699 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $120.72 |
52-Week Low | $58.33 | $113.17 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
IEI is trading at $113.57 with minimal daily movement (+0.08%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $114 and support at $113. Recent dividend payments of $0.37-$0.38 per share demonstrate shareholder returns, but key valuation metrics (P/E, P/S, P/B) are unavailable for fundamental assessment.
The outlook remains cautious due to the bearish technical setup and lack of fundamental visibility. Bond market volatility highlighted in recent news (Bloomberg, Reuters September 2026) could impact financial sector sentiment. Investment appeal hinges on forthcoming financial disclosures to validate valuation, while current technical resistance near $114 limits near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
